Falcon Wealth Planning Reduces Stake in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 2nd, 2023

Falcon Wealth Planning cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,593 shares of the company’s stock after selling 159 shares during the period. Falcon Wealth Planning’s holdings in Johnson & Johnson were worth $281,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Glassy Mountain Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at about $35,000. Retirement Financial Solutions LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at about $40,000. TD Capital Management LLC bought a new stake in Johnson & Johnson during the third quarter valued at about $48,000. Iron Horse Wealth Management LLC raised its holdings in Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares during the period. Finally, Cowa LLC bought a new stake in Johnson & Johnson during the third quarter valued at about $58,000. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $155.00 on Friday. The business’s fifty day simple moving average is $158.02 and its 200-day simple moving average is $167.16. The company has a market cap of $403.66 billion, a PE ratio of 23.00, a PEG ratio of 2.64 and a beta of 0.54. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The business had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 earnings per share. Analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s payout ratio is presently 67.06%.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Guggenheim began coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Atlantic Securities raised their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a report on Wednesday, January 25th. UBS Group began coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Citigroup lifted their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Finally, StockNews.com began coverage on Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.67.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.